Artículo
Trabectedin plus radiotherapy for advanced soft-tissue sarcoma: experience in forty patients treated at a sarcoma reference center
Autor/es | Hindi Muñiz, Nadia
Carrasco Garcia, Irene Sanchez Camacho, Alberto Gutierrez, Antonio Peinado, Javier Rincon, Inmaculada Santos Fernández, Paloma Sánchez Bustos, Paloma da Silva Moura, David Martín Broto , Javier |
Fecha de publicación | 2020-12-12 |
Fecha de depósito | 2021-02-16 |
Publicado en |
|
Resumen | Symptomatic control and tumoral shrinkage is an unmet need in advanced soft-tissue sarcoma (STS) patients beyond first-line. The combination of trabectedin and radiotherapy showed activity in a recently reported clinical ... Symptomatic control and tumoral shrinkage is an unmet need in advanced soft-tissue sarcoma (STS) patients beyond first-line. The combination of trabectedin and radiotherapy showed activity in a recently reported clinical trial in this setting. This retrospective series aims to analyze our experience with the same regimen in the real-life setting. We retrospectively reviewed advanced sarcoma patients treated with trabectedin concomitantly with radiotherapy with palliative intent. Growth-modulation index (GMI) was calculated as a surrogate of efficacy. Forty metastatic patients were analyzed. According to RECIST, there was one (2.5%) complete response, 12 (30%) partial responses, 18 (45%) disease stabilizations, and nine (22.5%) progressions. After a median follow-up of 15 months (range 2–38), median progression-free survival (PFS) and overall survival (OS) were 7.5 months (95% CI 2.8–12.2) and 23.5 months (95% CI 1.1–45.8), respectively. Median GMI was 1.42 (range 0.19–23.76), and in 16 (53%) patients, it was >1.33. In patients with GMI >1.33, median OS was significantly longer than in those with GMI 0–1.33 (median OS 52.1 months (95% CI not reached) vs. 8.9 months (95% CI 6.3–11.6), p = 0.028). The combination of trabectedin plus radiotherapy is an active therapeutic option in patients with advanced STS, especially when tumor shrinkage for symptomatic relief is needed |
Cita | Hindi Muñiz, N., Carrasco Garcia, I., Sanchez Camacho, A., Gutierrez, A., Peinado, J., Rincon, I.,...,Martín Broto , J. (2020). Trabectedin plus radiotherapy for advanced soft-tissue sarcoma: experience in forty patients treated at a sarcoma reference center. Cancers, 12 (12), 1-14. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Trabectedin Plus Radiotherapy ... | 1.928Mb | ![]() | Ver/ | |